|Bid||8.21 x 0|
|Ask||8.34 x 0|
|Day's Range||8.20 - 8.35|
|52 Week Range||6.00 - 16.20|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
ProMIS Neurosciences Inc. (T.PMN) hit a new 52-week high of $8.70 Wednesday. No news stories available ...
TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that, to meet the criteria to list its common shares on the Nasdaq Capital Market (“NASDAQ”), the Board of Directors has approved a 1-for-60 reverse share s
Announced that it has filed a registration statement on Form 10 with the United States Securities and ...